Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019064053) DOSING REGIMES FOR TREATMENT OF SYNUCLEINOPATHIES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/064053 International Application No.: PCT/IB2017/055981
Publication Date: 04.04.2019 International Filing Date: 28.09.2017
IPC:
C07K 14/47 (2006.01) ,A61K 39/00 (2006.01) ,C07K 16/18 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
46
from vertebrates
47
from mammals
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
Applicants:
PROTHENA BIOSCIENCES LIMITED [IE/IE]; Adelphi Plaza, Upper George's Street Dun Laoghaire Co. Dublin, A96 T927, IE
F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124 4070 Basel, CH
Inventors:
SOTO, Jay; US
NESS, Daniel Keith; US
KOLLER, Martin; US
MOULD, Diane; US
BOESS, Frank; CH
MARTIN-FRACKLAM, Meret; CH
COSSON, Valerie; CH
GRIMM, Hans Peter; CH
GIESCHKE, Ronald; CH
BELLI, Sara; CH
WEBER, Silke; CH
Priority Data:
Title (EN) DOSING REGIMES FOR TREATMENT OF SYNUCLEINOPATHIES
(FR) RÉGIMES POSOLOGIQUES DESTINÉS AU TRAITEMENT DE SYNUCLÉINOPATHIES
Abstract:
(EN) The invention provides dosage regimes for treatment of synucleinopathies. In one regime, a subject receives 3000-5000 mg of an antibody intravenously every 3-5 weeks. In another regime, a subject receives 1300-1700 mg of an antibody intravenously every 3-5 weeks.
(FR) L'invention concerne des régimes posologiques pour le traitement de synucléinopathies. Dans un régime, un sujet reçoit de 3000 à 5000 mg d'un anticorps par voie intraveineuse toutes les 3 à 5 semaines. Dans un autre régime, un sujet reçoit de 1300 à 1700 mg d'un anticorps par voie intraveineuse toutes les 3 à 5 semaines.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)